NOI_W81XWH22Q0024.pdf

THIS IS A NOTICE OF INTENT TO AWARD A SOLE-SOURCE CONTRACT AND IS NOT A REQUEST

FOR COMPETITIVE PROPOSALS.

The U.S. Army Medical Research Acquisition Activity (USAMRAA) intends to award a sole source basis in accordance FAR 13.106-1(b)(1)(i) to Lampire Biologic Labs, Inc. 3599 Farm School Rd.,Ottsville, PA 18942, as the only responsible source that can provide defibrinated rabbit blood to in support of research as the Walter Reed Institute of Research (WRAIR).

This acquisition is being conducted under FAR Part 12, Acquisition of Commercial Items and 13 Simplified Acquisition Procedures. Provisions and clauses in effect through Federal Acquisition Circular 2022-02 are incorporated.

The Walter Reed Army Institute of Research's (WRAIR) Leishmania Diagnostic Laboratory (LDL) is the only College of American Pathologists (CAP) certified diagnostic laboratory that specializes in the full spectrum of leishmaniasis diagnostics. This capability has been available at WRAIR since the early 1970’s and has been a (CAP) accredited laboratory since the year 2000. The WRAIR LDL has a broad array of assays to assist military practitioners with the diagnosis of this disease whether its clinical form is cutaneous, mucocutaneous or visceral from both the Old and the New World. The WRAIR LDL can assist the clinician in the best ways to sample lesions and suggest the best testing to maximize diagnostic yield. LDL completed a validation study to identify the best type of human and animal blood to provide most effective results. The identified defibrinated rabbit blood was verified as the most effective vehicle for this testing and research and is necessary for the continuation of this research.

The intended acquisition will be classified under North American Industry Classification System (NAICS) 325414 Biological Product (except Diagnostic) Manufacturing, with a size code of 1,250 employees. Product Service Code (PSC) 6515.

This announcement fulfills the synopsis requirements under FAR 5.102(a)(3) and 5.203(a).

USAMRAA intends to release a solicitation no sooner than fifteen (15) days after publishing this synopsis. This Special Notice of Intent (NOI) is not a request for competitive quotes. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no meaningful, written submissions are received by the date listed below, which reflects at least fifteen (15) days after the publication of this notice, the solicitation will be issued as a sole source requirement to Lampire Biological Labs, Inc.

All responses concerning this notice shall be emailed to Rebecca Wisner at rebecca.c.wisner.civ@mail.mil. Interested concerns must identify their capability in writing to the above e-mail address no later than 10:00 AM Eastern Daylight Time (EDT), 22 February 2022. No phone calls accepted.